Organon Teknika reaches agreement with Anagen
This article was originally published in Clinica
Following the withdrawal from its marketing agreement with Anagen last year, Organon Teknika has agreed to provide assay stocks, production equipment and instruments at no cost to Anagen. Sales of the instruments are expected to contribute £1 million ($1.5 million) to Anagen's cash reserves in the current year.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.